Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.~* Must have moderate to severe active non-segmental vitiligo.~Exclusion Criteria:~* History of human immunodeficiency virus (HIV) or positive HIV serology at screening,~* Infected with hepatitis B or hepatitis C viruses.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
- Cohort 2 (Type: EXPERIMENTAL): Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
- Cohort 3 (Type: EXPERIMENTAL): Maintenance dose A given QD for 24 weeks
- Cohort 4 (Type: EXPERIMENTAL): Maintenance dose B given QD for 24 weeks
- Cohort 5 (Type: EXPERIMENTAL): Maintenance dose C given QD for 24 weeks
- Cohort 6 (Type: PLACEBO_COMPARATOR): Placebo given QD for 24 weeks
- Extension Cohort 1 (Type: EXPERIMENTAL): 4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
- Extension Cohort 2 (Type: EXPERIMENTAL): Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
- Extension Cohort 3 (Type: EXPERIMENTAL): Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
- Extension Cohort 4 (Type: EXPERIMENTAL): Maintenance dose A given QD for 24 weeks
- Extension Cohort 5 (Type: EXPERIMENTAL): Maintenance dose B given QD for 24 weeks
- Extension Cohort 6 (Type: NO_INTERVENTION): Observation period for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).